

## **NCRI Cancer Conference**

**2 – 5 October 2005**

**Birmingham, U.K.**

## **Programme**

### **CME Accreditation**

The conference has been approved by  
The Federation of the Royal College of Physicians of the UK  
for 23 external CPD credits



## Event Programme

### Sunday 2 October 2005

- 13.00 – 15.30** Workshops (various)
- 15.45 – 16.00** **Alex Markham** (NCRI Chairman)  
Welcome address
- 16.00 – 16.30** **Jessica Corner (UK)**  
*The future research agenda: the perspective of people affected by cancer*
- 16.30 – 17.10** **Rick Kaplan (UK)**  
*Perspectives on clinical research in the UK versus the US: where are we behind and where can we lead?*
- 17.10 – 17.50** **Hugues de Thé (FRA)**  
*Modelling acute promyelocytic leukaemia pathogenesis through therapeutic response*
- 17.50 – 18.30** **Adrian Harris (UK)**  
*New angiogenic pathways regulated by hypoxia*
- 18.30 – 21.00** Opening Reception and Trade Exhibition

### Monday 3 October 2005

- 08.45 – 09.00** **Tony Kouzarides(UK)**  
*Introduction*  
**Jane Cope (UK)**  
*Introduction to the NCRI*
- 09.00 – 09.40** **William Kaelin (USA)**  
*The von Hippel-Lindau hereditary cancer syndrome: insights into oxygen sensing and cancer*
- 09.40 – 10.20** **Malcolm Pike (USA)**  
*Chemoprevention of female cancers in premenopausal women: new targets and implementing what we already know*
- 10.20 – 11.00** Coffee and Exhibition Viewing
- 11.00 – 11.40** **Hans Clevers (NED)**  
*Signalling pathways in the intestine*
- 11.40 – 12.20** **Norman Coleman (USA)**  
*Molecular radiation oncology*
- 12.20 – 15.00** LUNCH/Poster Session & Exhibition Viewing
- 15.00 – 17.15** Parallel Sessions
- 17.15 – 18.00** BREAK

**18.00 – 18.40**      **Sir David Lane (SNG)** – *The NTRAC Lecture*  
*Cyclin dependent kinases as targets for cancer therapy*



**18.40 – 19.20**      **John Condeelis (USA)** – *The Institute of Cancer Research Lecture*  
*Discovery and characterisation of an invasion signature for mammary tumour cells*



**19.30 – 20.30**      Civic Reception

**20.30**              Speakers' Dinner (By Invitation Only)

**Tuesday 4 October 2005**

**09.00 – 09.40**      **Mike Richards (UK)** – *The Hayman Lecture*  
*The contribution that research has made to the development of cancer strategy in the UK*



**09.40 – 10.20**      **R n  Bernardis (NED)**  
*High throughput loss of function genetic screens to identify cancer-relevant genes*

**10.20 – 11.00**      Coffee and Exhibition Viewing

**11.00 – 11.40**      **Patrick Johnston (UK)** – *The BACR Tom Connors Lecture*  
*Pharmacogenetics of colorectal cancer*



**11.40 – 12.20**      **Sir Richard Peto (UK)**  
*UK cancer mortality trends – The hazards of smoking and benefits of stopping*

**12.20 – 15.00**      LUNCH/Poster Session & Exhibition View

**15.00 – 17.15**      Parallel Sessions

**17.15 – 18.00**      BREAK

**18.00 – 18.40**      **Peter Jones (USA)**  
*Epigenetic therapy*

**18.40 – 19.20**      **Karen Vousden (UK)**  
*Cell death or survival in response to p53*


**19.30 – 20.30**      Drinks Reception

**20.30 – 00.00**      Conference Dinner & Party

**Wednesday 5 October 2005**

**09.00 – 12.15**      Parallel Sessions

**CLOSE OF MEETING**



## PARALLEL SESSIONS

Monday 3rd October

### **Clinical - Breast Cancer**

Hosted by: Bruce Ponder

- **Bruce Ponder (UK)**  
*The search for common predisposing genes*
- **Kornelia Polyak (USA)**  
*The tumour microenvironment and its role in breast cancer*
- **Mary Helen Barcellos-Hoff (USA)**  
*Emerging roles of TGFbeta in breast cancer*
- **Andrew Tutt (UK)**  
*Novel therapy strategies for BRCA1 and BRCA2 associated cancers*
- **Rob Clarke (UK)**  
*Isolation and characterization of human mammary stem cells*

### **Consumer Interest - Information - Addressing Patients' Needs**

Hosted by: Joanne Rule

- **Hilary Thomas (UK)**  
*Making links - information and the clinical trial*
- **Speaker to be confirmed**  
*Macmillan Listening Study*
- **Roy Grainger (UK)**  
*Patient information and peer review*
- **Venetia Franglen**  
*Case Study – The SUIT Trial of the Impact of Providing Generic Information about Research to Adult Cancer Patients prior to their treatment decision*
- **David Wright, Mary Sayers and Jenny Walton**  
*Collaborating with consumers in cancer research: Experience from the Macmillan Listening Study*

### **Therapeutic Development - Developing Drugs Against Oncogenic Proteins**

Hosted by: Paul Workman

- **Paul Workman (UK)**  
*Overview and Hsp90 molecular chaperone inhibitors*
- **Tim Green (UK)**  
*Pre-clinical and early clinical activity of the highly selective, orally available, dual Src/Abl kinase inhibitor AZD0530*
- **Peter Parker (UK)**  
*Monitoring and targeting signal transduction pathways; EGFR and PI3Kinase*  
[click here to view the abstract](#)
- **Saïd Sebtì (USA)**  
*Thwarting Ras and STAT3 aberrant signal transduction circuits to battle cancer*

- **Adam Sharp (UK)**  
*Novel chemical inhibitors of BAG-1 protein: protein interactions inhibit breast cancer cell growth and MAP kinase activity*

### Cancer Cell Biology - Epigenetics & Methylation

Hosted by: Wolf Reik

- **Wolf Reik (UK)**  
*Imprinting and epigenetic reprogramming in development and disease*
- **Manuel Esteller (ESP)**  
*Title to be confirmed*
- **Dirk Schubeler (SUI)**  
*Genome-wide and promoter specific analyses reveal sites of differential DNA methylation in normal and transformed human cells*
- **Charlotte Bradbury (UK)**  
*Sodium valproate combined with all-trans retinoic acid shows clinical and biological activity in high risk acute myeloid leukaemia*
- **Richard Bryant (UK)**  
*The polycomb group protein EZH2 promotes the proliferation and invasion of prostate cancer cells*
- **Gordon Strathdee (UK)**  
*HOX gene family members are frequently inactivated by DNA methylation in human leukaemia*

### Cancer Cell Biology - Metastasis including Stromal Cell Tumour Interactions

Hosted by: Margaret Frame

- **Margaret Frame (UK)**  
*Calpain 2- and Src-dependence define a requirement for integrin turnover during distinct modes of tumour cell invasion*
- **Peter Friedl (GER)**  
*Plasticity in cancer invasion: shifting integrin and protease requirements*
- **Mikala Egeblad (USA)**  
*Title to be confirmed*
- **Karin de Visser (NED)**  
*Inflammation-associated cancer development is B lymphocyte dependent*
- **Erik Sahai (UK)**  
*In vivo imaging of squamous cell carcinoma invasion*

### Clinical - Modern Cancer Screening

Hosted by: Alan Ashworth

- **Emanuel Petricoin (USA)**  
*Use of the low molecular weight range circulatory proteome for biomarker identification: vision for combining with imaging modalities*
- **Wendy Atkin (UK)**  
*A new NHS screening programme for bowel cancer screening: challenges and potential rewards*
- **Julian Peto (UK)**  
*What cervical cancer screening did*

- **Gareth Williams (UK)**  
*New markers for cancer detection*
- **Jenny Donovan (UK)**  
*Evaluating prostate cancer treatment and the potential impact of screening: The Protect Trial and comparison arm*

**NCRI Clinical Study Group – Complementary Therapies** (note: this parallel session will take place at 12:30 till 17:00)

Hosted by: Susie Wilkinson

12.30 – 12.40 **Susie Wilkinson**

*Introduction*

12.40 – 13.05 **Janet Richardson/Karen Pilkington**

*Presentation by Research Council for Complementary Medicine*

*The long and winding road: Tracking down the evidence in CAM and cancer*

*Discussion*

13.05 – 13.15 **Liz Thompson**

*A randomised, double-blind, placebo controlled, clinical trial to assess the efficacy of the homeopathic medication Stomatect-spray in the prevention of chemotherapy-induced stomatitis in children*

13.15 – 13.25 **Debbie Sharp**

*The impact of relaxation and guided imagery training on the symptoms and quality of life in women with ovarian cancer undergoing chemotherapy: a randomised trial*

13.25 – 13.35 **Kate Thomas**

*The development and validation of a patient-centred outcome tool for use in cancer support care utilising complementary therapies*

13.35 – 13.45 **Susie Wilkinson**

*Helping with Touch or Talk (TOT). A multi-centre randomised controlled trial to examine the clinical and cost-effectiveness of cognitive behaviour therapy, aromatherapy massage and standard care for cancer patients with symptoms of depression and anxiety*

13.45 – 13.55 **Speaker to be confirmed**

*Prospective study of safety in acupuncture: patient and practitioner perspectives*

13.55 – 14.10 **Liz Thompson**

*Presentation 1 - Homeopathy for symptoms of oestrogen withdrawal in breast cancer survivors- a review of recent trials and the challenge of appropriate research methodologies for complex interventions*

14.10 – 14.25 **University of Southampton**

*Presentation 2 - Complementary and alternative therapy use among people undergoing cancer treatment*

*Discussion*

14.25 - 14.40 **Debbie Sharp**

*Presentation 3 - CAM use amongst male cancer patients: reasoned decision-making or 'clutching at straws'?*

*Discussion*

- 14.40 – 14.55 **Edzard Ernst**  
*Presentation 4 - Ukrain – a new cancer cure? A systematic review of randomised clinical trials*  
*Discussion*
- 14.55 **Susie Wilkinson**  
*Conclusion/Discussion –*

**NCRI Clinical Study Group – Lung Cancer** *(note: this parallel session will take place at 12:30 till 15:00)*

Hosted by: Tim Eisen

- 12.30 – 12.35 **Tim Eisen**  
*INTRODUCTION*
- 12.35 – 12.45 **Tim Eisen**  
*Outcomes of the progress review and restructuring of the group*
- 12.45 – 13.05 **Tim Eisen**  
*Current development and future priorities of the Mesothelioma sub-group*
- 13.05 – 13.25 **Mike Peake**  
*Current development and future priorities of the Sceptre Sub-group*
- 13.25 – 13.45 **John Field**  
*Current development and future priorities of the Translational Sub-group*
- 13.45 – 14.05 **Allan Price**  
*Current development and future priorities of the NSCLC Stage I-III A SCLC LD Sub-group*
- 14.05 – 14.25 **David Ferry**  
*Current development and future priorities of the NSCLC Stage IIIB/IV SCLC ED Sub-group*
- 14.25 – 15.00 **Stephen Falk**  
*Current development and future priorities of the Rare Tumours Sub-group*

**NCRI Clinical Study Group – Testis Cancer**

Hosted by: Robert Huddart

- 15.00 – 15.05 **Robert Huddart**  
*INTRODUCTION*
- RESULTS OF CLOSED TRIALS**
- 15.05 – 15.30 **Speaker to be confirmed**  
*Final results of MRC TE08: A randomised trial of CT scan-frequency in Stage I NSGCT*
- 15.30 – 16.00 **Robert Huddart**  
*Results of CR UK TE22 trial: A FDG PET in the prediction of relapse in stage I non-seminomatous germ cell tumour*
- NEW RESEARCH / TRIAL IDEAS**
- 16.00 – 16.30 **Jonathan Joffe**  
*UK Management of stage I seminoma. Results of survey and proposals for national trial*
- 16.30 16.55 **Jonathan Shamash (to be confirmed)**  
*Randomised trial – A randomised phase III study of short (30 minute) versus long (72 hour) infusion Bleomycin for patients with IGCCCG good prognosis germ cell tumours, TE3. A NCRI trial*
- 16.55 – 17.00 **Robert Huddart**  
*An overview and discussion of the NCRI testis cancer portfolio*

### NCRI Clinical Study Group – Upper GI Cancer

Hosted by: David Cunningham

15.00 – 15.05 **David Cunningham**  
*INTRODUCTION*

15.05 – 15.35 **John Neoptolemos**  
*Current national and international trials in Pancreatic Cancer –*

15.35 – 16.05 **James Garden (UK)**  
*Current National Trials in Hepatobiliary cancer*

16.05 – 16.35 **Tom Crosby (UK)**  
*Current Trials of Chemo-radiotherapy in Upper GI Cancer*

16.35 – 17.15 **Bill Allum**  
*Current National Trials in Oesophago gastric Cancer*

### Prevention - Hormonal Manipulation

Hosted by: Valerie Beral

- **Tony Howell (UK)**  
*Anti-oestrogens and related therapies to prevent breast cancer*
- **Henri Rochefort (FRA)**  
*Markers of response to ovarian hormones in early steps of human mammary carcinogenesis*
- **Tim Key (UK)**  
*Endogenous hormones and cancer*
- **Valerie Beral (UK)**  
*Potential for preventing cancer in women by hormonal manipulation*

### Supportive & Palliative Care - Improving the Management of Emotional Distress

Hosted by: Amanda Ramirez

- **David Kissane (USA)**  
*Improving clinical depression in advanced breast cancer: The Spiegel replication RCT*
- **Michael Sharpe (UK)**  
*RCT of nurse led intervention for major depression*
- **Susie Wilkinson (UK)**  
*RCT of aromatherapy in the management of anxiety and depression*
- **Amanda Ramirez (UK)**  
*Poor mental health of cancer consultants*

**Tuesday 4th October**

### Clinical - Advances in Pancreatic Cancer

Hosted by: Nick Lemoine

Supported by Pancreatic Cancer Research Fund with CR-UK

- **David Tuveson (USA)**  
*Advances in modelling pancreatic cancer*



- **Malte Buchholz (GER)**  
*The diagnostic microchip for pancreatic cancer*
- **Tatjana Crnogorac-Jurcevic (UK)**  
*Molecular markers for pancreatic adenocarcinoma*
- **John Neoptolemos (UK)**  
*Design and clinical applications of algorithms for early diagnosis*
- **Margaret Tempero (USA)**  
*Novel therapeutics – the end of nihilism*

### British Oncological Association Session - Future Direction of Radiotherapy

Hosted by: Robert Coleman and Ros Eeles (*note: this parallel session will take place at 13:00 till 14:45*)



- **Norman Coleman (USA) BOA Lecture**  
*Future role of radiotherapy: the NIH view*
- **Trevor Roberts (UK)**  
*The structure of national radiotherapy services for the year 2010*
- **Peter Hoskin (UK)**  
*Radiotherapy trials in the UK – is this the renaissance?*
- **Bleddyn Jones (UK)**  
*Proton treatment in the UK: Do we really need it?*

[Click here for details of full session](#)

### Consumer Interest - Trials to Treatment – should we be getting there quicker?

Hosted by: Frank Rhodes

- **Peter Littlejohns (UK)**  
*Developing new treatments faster – a research perspective*
- **Paul Moss (UK)**  
*Title to be confirmed*
- **Roger Wilson (UK)**  
*Case Study – The treatment of GIST*

### Cancer Cell Biology - DNA Repair

Hosted by: Stephen Jackson

- **Stephen Jackson (UK)**  
*The DNA-damage response: from molecular insights towards new approaches to anti-cancer therapy*
- **Simon Boulton (UK)**  
*DNA double-strand break repair and cancer predisposition*
- **Stephen West (UK)**  
*Homologous recombination and the maintenance of genome stability*
- **Tomas Lindahl (UK)**  
*Strategies of repair of alkylated DNA*
- **Christopher Mathew (UK)**  
*New genes and protein complexes link Faconi Anaemia to DNA repair*

### Clinical - Lung Cancer

Hosted by: Tim Eisen

- **Tim Eisen (UK)**  
*Title to be confirmed*
- **Rafael Rosell (ESP)**  
*Predictive markers for customising and targeted therapies*
- **Roman Thomas (USA)**  
*Genomic Approaches to Lung Cancer*
- **Thomas Lynch (USA)**  
*Targeted Therapy of NSCLC: Role of EGFR TK mutations in selecting agents for treatments*

### NCRI Clinical Study Group – Colorectal Cancer

Hosted by: John Scholefield

- 13.30 - 13.35 **John Scholefield (UK)**  
*Welcome and introduction to the aims of this session*
- 13.35 – 13.45 **John Scholefield (UK)**  
*Overview of current trials in portfolio*
- HAVE NCRN TRIALS CHANGED PRACTICE?**
- QUASAR**
- 13.45 – 13.55 **Richard Gray (UK)**  
*What do the results mean?*
- 13.55 – 14.05 **Rob Glynn-Jones (UK)**  
*What do they mean in terms of changing practice?*
- CLASSIC**
- 14.05 – 14.15 **Philip Quirke (UK)**  
*What do the results mean?*
- 14.15 – 14.25 **D Morton (UK)**  
*What do they mean in terms of changing practice?*
- FOCUS**
- 14.25 – 14.35 **Matt Seymour (UK)**  
*What do the results mean?*
- 14.35 – 14.45 **Will Stewart (UK)**  
*What do they mean in terms of changing practice?*
- 14.45 – 15.00 Question and answer session
- 15.00 – 15.20 Tea/Coffee
- NEW TRIALS**
- 15.20 – 15.30 **John Primrose (UK)**  
*FACS relaunch*
- 15.30 – 15.50 **Matt Seymour (UK)**  
*PICCOLO*
- 15.50 – 16.05 **Rob Glynn-Jones (UK)**  
*CHRONICLE*
- 16.05 – 16.15 Questions and answer session

### NEW DEVELOPMENTS

- 16.15 – 16.25 **David Sebag-Montefiore (UK)**  
*Developments in Rectal Cancer*
- 16.25 – 16.40 *What is happening in the Adjuvant Portfolio*  
**David Kerr (UK)** (QUASAR 2)  
**Jim Cassidy (UK)** (SCOT)
- 16.40 – 16.50 **Bob Steele (UK)**  
*New developments in prevention, screening and early diagnosis*
- 16.50 – 17.00 **John Scholefield (UK)**  
*Closing remarks*

### NCRI Clinical Study Group – Head and Neck Cancer

Hosted by: Martin Robinson

- 15.00 – 15.05 **Martin Robinson (UK)**  
*Introduction*

### CURRENT TRIALS

- 15.05 – 15.05 **Martin Robinson (UK)**  
*MARCHON*
- 15.15 – 15.25 **Catherine West (UK)**  
*MARCHON - TRANS*
- 15.25 – 15.35 **Christopher Nutting (UK)**  
*PARSPORT and HOTTER*
- 15.35 – 15.45 **Martin Birchall (UK)**  
*EASTER*

### THYROID

- 15.45 – 15.55 **Jayne Franklyn (UK)**  
*HILO*
- 15.55 – 16.05 **John Buscombe (UK)**  
*Imaging in thyroid cancer*

### POSSIBLE NEW TRIALS

- 16.05 – 16.05 **J Brown (UK)**  
*Post-operative radiotherapy in head and neck cancer trial*
- 16.15 – 16.25 **K McLennan (UK)**  
*Translational studies*
- 16.25 – 16.35 **To be confirmed**  
*Palliative therapy proposal*
- 16.35 – 16.45 **Professor McGurk (UK)**  
*Sentinel node biopsy study*
- 16.45 – 17.00 **I Hutchinson (UK)** (SEND trial)  
*Speakers to be confirmed*

### NCRI Clinical Study Group – Melanoma / Renal Cancer

Hosted by: Martin Gore & Barry Hancock

12.30 - 13.00 **Tim Eisen (UK)**  
*Latest news on signal inhibition*

13.00 – 13.30 **Robert Hawkins (UK)**  
*Enhancing host responses to immunotherapy*

#### CURRENT TRIALS AROUND THE WORLD

13.30 – 13.45 **Dr David Chao (UK) / Professor Martin Gore (UK)**  
*Melanoma*

13.45 – 14.00 **Emilio Porfiri (UK) / Professor Barry Hancock (UK)**  
*Renal Cancer*

#### CURRENT TRIALS IN THE UK

14.00 – 14.15 **Martin Gore (UK)**  
*Melanoma*

14.15 – 14.30 **Barry Hancock (UK)**  
*Renal Cancer*

### NCRI Clinical Study Group – Radiotherapy

Hosted by: Peter Hoskin

15.00 – 15.05 **Peter Hoskin (UK)**  
*Introduction*

#### RADIOTHERAPY TRIAL UPDATE

15.05 – 15.20 **Christopher Nutting (UK)**  
*PARSPORT*

15.20 – 15.35 **John Yarnold (UK)**  
*FAST/IMPORT (Physics)*

15.35 – 15.50 **David Dearnaley (UK)**  
*RT01/CHIPP*

15.50 – 16.05 **Peter Hoskin (UK)**  
*BNLI lymphoma dose trial*

16.05 – 16.20 **D Talbot (UK)**  
*AQ4N*

16.20 – 17.00 **Pat Price (UK)**  
*ACCORN*

### NCRN Clinical Trials Showcase

Hosted by: Rick Kaplan

Speakers to be confirmed



### Clinical - Ovarian Cancer

Hosted by: Stan Kaye

- **Robert Brown (UK)**  
*Drug resistance in ovarian cancer: obstacle or target?*
- **Hani Gabra (UK)**  
*Molecular profiling/gene expression analysis in ovarian cancer and potential for individualised treatment*
- **Ian Jacobs (UK)**  
*NCRI screening trials*
- **Stan Kaye (UK)**  
*Update on management of ovarian cancer, including novel approaches*  
[click here to view the abstract](#)
- **Julia Wilson (UK)**  
*Expression of the chemokine receptor CXCR4 alters the behaviour of ovarian cancer cells in vitro and in vivo*

### Clinical - Paediatric Oncology

Hosted by: Andy Pearson

- **Andy Pearson (UK)**  
*The challenges for clinical trials in childhood cancer and new drug development in the next 5 years*
- **Javed Khan (USA)**  
*Inferring tumour progression models using array CGH data*
- **Nazneen Rahman (UK)**  
*Aneuploidy-cancer predisposition syndromes - new insights into the links between the mitotic spindle checkpoint and childhood cancer development*
- **AV Moorman (UK)**  
*Molecular cytogenetic characterisation of childhood acute lymphoblastic leukaemia (all) and correlation with outcome*
- **Debbie Graham (UK)**  
*Mapping and analysis of tumour suppressor genes (TSGs) on chromosome 10q in childhood medulloblastoma*
- **Aliki Taylor (UK)**  
*Risk of breast cancer in female survivors of childhood Hodgkin's disease in Britain*

### Prevention - General, including Screening and Vaccination

Hosted by: Valerie Beral

- **Charles Lacey (UK)**  
*Human Papillomavirus vaccines against cervical cancer*
- **Andy Hall (UK)**  
*Primary liver cancer – prevention by vaccination & aflatoxin reduction*
- **Sue Moss (UK)**  
*The potential of screening to prevent cancer deaths in the UK*
- **Jane Wolstenholme (UK)**  
*The Economics of Cancer Screening*

### Cancer Cell Biology - Stem Cells

Hosted by: Fiona Watt

- **Sean Morrison (USA)**  
*Tumour suppressor genes regulate stem cell self-renewal*
- **Fiona Watt (UK)**  
*Role of stem cells in epidermal tumour formation.*
- **Dominique Bonnet (UK)**  
*Normal and leukaemic stem cells*
- **Amanda Fisher (UK)**  
*Epigenetic profiles predict stem cell potency*
- **Matthew Smalley (UK)**  
*Molecular dissection of the mouse mammary gland reveals a SCA-1-/CD49F- population which contains cells with stem cell ability*

### Supportive & Palliative Care - Improving Symptom Management and overall Patient Care

Hosted by: Lesley Fallowfield

- **Charles Cleeland (USA)**  
*Improving symptom management in patients with cancer*
- **Galina Velikova (UK)**  
*Routine symptom assessment, subsequent communication and patient well being*
- **Lesley Fallowfield (UK)**  
*Effective communication with patients who have cancer*
- **Irene Higginson (UK)**  
*Title to be confirmed*

### Therapeutic Development - Tumour Suppressor Gene and Apoptosis Targets

Hosted by: Herbie Newell

- **Herbie Newell (UK)**  
*Overview of approaches to target tumour suppressor gene loss in cancer*
- **Lyubomir Vassilev (USA)**  
*Small-molecule antagonists of the p53-MDM2 interaction: promising new agents for cancer therapy*
- **Saul Rosenberg (USA)**  
*Novel antitumour agents that target the Bcl-2 family of anti-apoptotic proteins*
- **Jean-Pierre Issa (USA)**  
*Title to be confirmed*
- **Melanie Howell (UK)**  
*Pharmacological inhibition of NF- $\kappa$ B selectively induces apoptosis in chronic lymphocytic leukaemia cells*

Wednesday 5<sup>th</sup> October

### Therapeutic Development - Angiogenesis

Hosted by: Adrian Harris

- **Roy Bicknell (UK)**  
*Identification of novel targets in the tumour vasculature; Robo4*
- **Gordon Jayson (UK)**  
*Imaging angiogenesis*
- **George Sledge, Jr (USA)**  
*Clinical development of VEGF-targeting agents*
- **Robert Kerbel (CA)**  
*Markers and mechanisms for metronomic antiangiogenic chemotherapy*
- **Emma Rennel (UK)**  
*VEGF 165b expression inhibits growth of human renal cell carcinomas xenotransplanted into nude mice*
- **Carolyn Staton (UK) – (BACR Translational Research Award)**  
*Discovery and development of alphastatin, a novel anti-angiogenic and anti-vascular agent derived from humanfibrinogen*

### British Oncological Association Session – Integration of radiology in radiotherapy: the promise of image-guided treatment planning

Hosted by: Chris Nutting and Joe O'Sullivan



- **QS Ng (UK)**  
*Tumour anti-vascular effects of Radiotherapy (RT) combined with weekly combretastatin A4 Phosphate (CA4P) compared with RT alone*
- **RA Sharma (UK)**  
*Yttrium-90 chemoradiation treatment of liver metastases from colorectal cancer: International phase I trial*
- **MT Guerrero Urbano (UK)**  
*Results of Intensity Modulated Radioterapy (IMRT) in patients with locally advanced thyroid cancer: Report of acute toxicity*
- **R Singhal (UK)**  
*Effect of cavity shaving on re-operation rate following breast conserving surgery*
- **Marcel Van Herk (NED) - The Bob Champion Cancer Trust Lecture**  
*Image guided radiotherapy: current state of the art*
- **Pat Price (UK)**  
*The application of functional imaging to radiotherapy planning*
- **Christopher Nutting (UK)**  
*Current status and future role of IMRT*

[Click here for details of full session](#)

### Cancer Cell Biology - Cancer Genetics

Hosted by: Doug Easton

- **Doug Easton (UK)**  
*Title to be confirmed*
- **Allan Balmain (USA)**  
*Mouse models for the analysis of human cancer susceptibility*
- **Michael Stratton (UK)**  
*Title to be confirmed*
- **Gerry Thomas (UK)**  
*The Chernobyl legacy: Relationship between radiation exposure RET rearrangement and BRAF mutation in childhood thyroid cancer*
- **Paul Wright (UK)**  
*Identification of oestrogen-regulated genes in human breast cancer cells using DNA microarrays*

### Consumer Interest - Patients' Debate

Hosted by: Roger Wilson and Alf Oliver

- **Alison Eastwood (UK) - Matthew Hallsworth (UK)**  
*Public Awareness of Cancer Research*
- *Formal debate: the motion - Placebo has no place in cancer trials*  
Proposed by: **Keith Taylor (NCRI CLG)**                      Seconded by: **tba**  
Against the motion: **Fergus Macbeth (UK)**                      Seconded by: **Roger Wilson (UK)**
- **Ernest Parry (UK), Karen Wilman (UK) and David Ardron (UK), Vivienne Brown (UK) and Phil Cotterell (UK)**  
*Changing the dynamics of the research culture*

### Clinical - Gastrointestinal Cancer

Hosted by: David Cunningham

- **Janusz Jankowski (UK)**  
*Preventing cancers of the gastrointestinal tract*
- **Gina Brown (UK)**  
*Improving outcomes for patients with rectal cancer*
- **John Neoptolemos (UK)**  
*Progress in pancreatic cancer*
- **David Cunningham (UK)**  
*Targeted treatments in gastrointestinal cancer*

### Cancer Cell Biology - Immunology

Hosted by: Peter Johnson

- **Peter Johnson (UK)**  
*Immunostimulatory antibodies*
- **Thomas Wolfel (GER)**  
*Targets of the autologous anti-tumour response*

- **Laurence Zitvogel (FRA)**  
*Immunopharmacology promoting NK cell activation for cancer therapeutics*
- **Paul Moss (UK)**  
*Title to be confirmed*
- **Neil Steven (UK)**  
*A novel non-viral transfection system for dendritic cells: results of a pilot trial of vaccination against melanoma antigens*

### **Cancer Cell Biology - Infection and Cancer**

Hosted by: Chris Boshoff

- **Max Parkin (UK)**  
*Cancer: the global contribution of infection*
- **Alan Rickinson (UK)**  
*Immunotherapies for nasopharyngeal carcinoma and Hodgkin's disease*
- **Diane Harper (USA)**  
*A vaccine for cervical cancer*
- **Mary Kroll (UK)**  
*Trends in childhood leukaemia, Britain 1974-98*
- **Andrea Varro (UK)**  
*Role of MMP-7 in epithelial-mesenchymal signalling*
- **Seonaidh Cotton (UK)**  
*Lifestyle factors associated with high-risk HPV infection in women with cervical smear showing bordering nuclear abnormality*
- **Seyyed Rezaee (UK)**  
*Suppression of inflammatory reactions by recombinant KSHV vOX-2:Fc protein*

### **NCRI Clinical Study Group – Breast**

Hosted by: Robert Coleman

*“Endocrine manipulation for breast cancer prevention and treatment”*

- 9.00 – 9.25 **Mitch Dowsett**  
*Targeting targeted therapy in breast cancer*
- 9.25 – 9.50 **Ian Smith**  
*Making the best use of aromatase inhibitors in operable breast cancer.  
Current status and future questions*
- 9.50 – 10.15 **Chairs, speakers, Dan Rea and Robert Leonard**  
*Panel discussion*
- 10.15- 10.45 *tea / coffee*
- 10.45 – 11.10 **Andrew Wardley**  
*Breakthrough of the decade?  
First results of Adjuvant and Neoadjuvant trials with trastuzumab (Herceptin)*

- 11.10 – 11.35 **Rob Stein**  
*Herceptin failure in advanced breast cancer: controversies and new clinical trials*
- 11.35 – 12.00 **David Cameron**  
*Clinical approach to new treatment targets in breast cancer*
- 12.00 – 12.15 **Chairs, speakers, Peter Canney**  
*Panel discussion*

### Prevention - Behaviour change

Hosted by: Jane Wardle

- **Jane Wardle (UK)**  
*Tackling the obesity epidemic*
- **Robert West (UK)**  
*Projected national smoking prevalence and smoking-related death rates following actual and potential policy initiatives in the UK*
- **Gary Whitlock**  
*Obesity and premature death: a prospective study of 500 000 men and 300,000 women*
- **Peter Boyle (FRA)**  
*IARC and cancer control worldwide*

### Clinical - Prostate Cancer

Hosted by: David Neal

- **David Neal (UK)**  
*Clinical background to prostate cancer – potential areas for targeting current and future research*
- **William Nelson (USA)**  
*Early initiation of prostate cancer – potential for chemoprevention*
- **Val Macaulay (UK)**  
*The IGF axis as potential target for treatment of prostate cancer*
- **Ian Mills (UK)**  
*Effects of a membrane trafficking protein on androgen response*
- **Joe O'Sullivan (UK)**  
*A Phase 2 study of high activity Rhenium-186 HEDP with autologous peripheral blood stem cell transplant in progress hormone refractory prostate cancer metastatic to bone*
- **Griet Vanpoucke (UK)**  
*Identification of mesenchymal genes involved in prostate development and carcinogenesis using serial analysis of gene expression (SAGE)*

### **Cancer Cell Biology - Radiobiology**

Hosted by: Gillies McKenna

- **John Thacker (UK)**  
*The influence of DNA repair genes on radiation sensitivity and genetic stability in mammals*
- **Gillian Tozer (UK)**  
*Tumour vasculature as a target for treatment*
- **Gillies McKenna (USA)**  
*Signal transduction targets for modifying radiation responses*
- **A Chalmers (UK)**  
*DNA repair mechanisms underlying the radiosensitising effects of chemical inhibitors of PARP-1*
- **Kaye Williams (UK) - (BACR/AZ Young Scientist Frank Rose Award)**  
*Combining HIF-1 targeted approaches with conventional anti-cancer treatments*

## WORKSHOPS

Sunday 2nd October

### **NCRI Cancer Informatics Initiative Workshop**

Co-Chairs: Richard Begent and Ken Buetow

- 13.00 – 13.45 **Alex Markham**  
(Chair, NCRI Informatics High Level Steering Committee, UK)  
*Introduction and Welcome*
- 13.15 – 13.45 **Ken Buetow**  
(Director of NCICB and caBIG programme, USA)  
*Cancer Informatics*
- 13.45 – 14.15 **Sir Mike Brady**  
(Principal Investigator, e-DiaMoND project, UK)  
*Medical Imaging*
- 14.15 – 14.45 **Carlos Caldas**  
(Principal Investigator, CancerGRID project, UK)  
*CancerGRID - A Demonstrator for the NCRI Informatics Initiative*
- 14.45 – 15.00 **Richard Begent**  
(Chair, NCRI Informatics Task Force, UK)  
*Title to be confirmed*

### **Molecular Targeting in Cancer**

(Sponsored by: The Cancer Recognised Research Group in Northern Ireland and The Research and Development Office of the HPSS NI)

Joint chairs: Stephanie McKeown and Paddy Johnston

- 13.00 – 13.45 **Keynote lecture:**  
**Steve Jackson**  
The Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge, UK.  
*“Molecular targeting in cancer: lessons from the field of DNA repair”*
- 13.45 – 14.00 **Timothy R Wilson, Wendy L Allen, Ultan McDermott, Miranda McEwan, Leona Galligan and Patrick G Johnston, Daniel B. Longley.**  
Drug Resistance Group, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, N. Ireland.  
*c-FLIP: a new target for colon cancer?*
- 14.00 – 14.15 **Andrea Valentine, Hayley McKeen, Helen O. McCarthy, Kerry McAlpine, Keeva McClelland, David G. Hirst, Tracy Robson.**  
Molecular Therapeutics Group, School of Pharmacy, Queen’s University Belfast, Belfast, N.Ireland.  
*Characterisation of a novel HSP90 interacting protein, FKBP-L/DIR1; implications for pathways controlling cell growth and survival.*
- 14.15 – 14.30 **Luciano A. Guerreiro Lucas<sup>1,2</sup>, Christopher A. Mitchell<sup>1</sup>, Paul Barber<sup>2</sup>, Keyi Jiang<sup>3</sup>, Gerald A. Soff<sup>3</sup>, Gillian M. Tozer<sup>2</sup>.**  
1 Centre for Molecular Biosciences, University of Ulster, Coleraine, N. Ireland;

2 Gray Cancer Institute, Northwood, London, UK;  
 3 Northwestern University, Chicago, IL, USA.  
*Molecular targeting of angiogenesis - an intravital imaging study.*

14.30 – 14.45 **Christopher J Watson<sup>1</sup>, Hugh O’Kane<sup>1</sup>, Perry Maxwell<sup>1,2</sup>, Kate E. Williamson<sup>1</sup>**  
 1 Uro-Oncology Research Group, Department of Pathology, Queen’s University Belfast, Northern Ireland  
 2 Royal Hospitals Trust, Belfast, N. Ireland.  
*In vitro and in vivo evidence that mitomycin-c chemotherapy up-regulates the death receptor Fas in bladder cancer cells.*

14.15 – 15.00 General discussion

15.00 Tea / coffee

[Click here for related Abstracts](#)

### Wednesday 5th October

#### Supportive and Palliative Care - Interactive Workshop on Communicating about Randomised Control Trials

Hosted by: Lesley Fallowfield

Speakers to be confirmed

#### Workshop on Cancer Associated Thrombosis 12.30 – 2pm

Chairmen: Michael Peckham, London Stan Kaye, London

12.15 – 12.45 **Collect Japanese lunch-box**  
 12.45 – 12.50 **Michael Peckham**  
*Introduction:*  
 12.50 – 13.20 **A.K. Kakkar**  
*Prevention and treatment of VTE in cancer*  
 13.20 – 13.40 **A Young**  
*Catheter associated thrombosis*  
 13.40 – 13.55 **Questions**  
 13.55 – 14.00 **Stan Kaye**  
*Closing remarks.*

#### Translational Research in Clinical Trials Workshop

Hosted by: Peter Parker

Supported by CR-UK TRICC in association with NTRAC

- **Arul Chinnaiyan (USA)**  
*The success story: from trial samples to clinical data*
- **Doug Altman (UK)**  
*The reality check: statistics and samples*
- **Emanuel Petricoin (USA)**  
*Proteomics for clinical applications and molecular medicine*

- **Phil Quirke (UK)**  
*Trials, imaging and pathology*
- **James Brenton (UK)**  
*Clinical significance of functional genomics*

**Workshop Panel:**

**– At last the clinical trial is in place – but what samples should I collect and what should I do with them?**

Hosted by: Carlos Caldas

[Click here for details of full session](#)